Case report: Bullous pemphigoid associated with sintilimab therapy for pMMR/MSS colorectal cancer

Ting Wang; Qianwen Shao; Chunmei Xiao; Lianke Liu

doi:10.3389/fonc.2023.1124730

Case report: Bullous pemphigoid associated with sintilimab therapy for pMMR/MSS colorectal cancer

Front Oncol. 2023 Mar 14:13:1124730. doi: 10.3389/fonc.2023.1124730. eCollection 2023.

Authors

Ting Wang¹, Qianwen Shao¹, Chunmei Xiao¹, Lianke Liu¹

Affiliation

¹ Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.

Abstract

Immunotherapy has become a very effective treatment for many cancers. It has a unique set of immune system-related adverse effects, collectively known as immune-related adverse events (irAEs). Skin toxicities are the most common irAEs, of which bullous pemphigoid, although rare, is potentially life-threatening and affects patients' survival. In this article, we report the treatment of bullous pemphigoid caused by programmed cell death protein-1 (PD-1) in a case of proficient mismatch repair (pMMR)/microsatellite stable (MSS) colorectal cancer. No significant adverse effects were observed in the patient after methylprednisone was tapered to 4 mg twice a day. No new skin lesions occurred recently in the patient and the original skin lesions healed. In particular, the patient's immunotherapy was not stopped and the best outcome was a partial remission of the disease, lasting for more than 8 months.

Keywords: PD-1; bullous pemphigoid; fruquintinib; pMMR/MSS mCRC; sintilimab.

Publication types

Case Reports

Grants and funding

This article was supported by the Jiangsu Provincial Science and Technology Department Clinical Frontier Technology (BE2020783), project name: Construction of integrated treatment system for advanced gastric and esophageal cancer advanced after chemoradiotherapy using photodynamic combined siRNA/miRNA nanocarriers under endoscope.